Survivin is a member of the inhibitor of apoptosis (IAP) gene family that has attracted attention from several viewpoints of basic and translational research. Its cell cycle-regulated expression at mitosis and association with the mitotic apparatus have been of interest to cell biologists studying faithful segregation of sister chromatids and timely separation of daughter cells. Investigators interested in mechanisms of apoptosis have found survivin an evolving challenge: while survivin inhibits apoptosis in vitro and in vivo, this pathway may be more selective as compared to cytoprotection mediated by other IAPs. Finally, basic and translational researchers in cancer biology have converged on survivin as a pivotal cancer gene, not simply for its sharp expression in tumors and not in normal tissues, but also for the potential exploitation of this pathway in cancer diagnosis and therapy. The objective of the present contribution is to line up current evidence and emerging concepts on the multifaceted functions of survivin in cell death and cell division, and how this pathway is being pursued for novel cancer therapeutic strategies.
Survivin is a member of the inhibitor of apoptosis (IAP) gene family that has attracted attention from several viewpoints of basic and translational research. Its cell cycle-regulated expression at mitosis and association with the mitotic apparatus have been of interest to cell biologists studying faithful segregation of sister chromatids and timely separation of daughter cells. Investigators interested in mechanisms of apoptosis have found survivin an evolving challenge: while survivin inhibits apoptosis in vitro and in vivo, this pathway may be more selective as compared to cytoprotection mediated by other IAPs. Finally, basic and translational researchers in cancer biology have converged on survivin as a pivotal cancer gene, not simply for its sharp expression in tumors and not in normal tissues, but also for the potential exploitation of this pathway in cancer diagnosis and therapy. The objective of the present contribution is to line up current evidence and emerging concepts on the multifaceted functions of survivin in cell death and cell division, and how this pathway is being pursued for novel cancer therapeutic strategies. Oncogene (2003 Oncogene ( ) 22, 8581-8589. doi:10.1038 Keywords: survivin; apoptosis; cell cycle; cancer; checkpoint Survivin structure-function At 16.5 kDa, survivin is the smallest mammalian member of the inhibitor of apoptosis (IAP) gene family (Salvesen and Duckett, 2002) . Structurally, it contains a single Baculovirus IAP Repeat (BIR), an B70-aminoacid zinc-finger fold that is the hallmark of all IAPs and an extended -COOH terminus a-helical coiled-coil, but no other identifiable domain (Ambrosini et al., 1997) typically found in IAPs. Based on X-ray crystallography of the human (Chantalat et al., 2000; Verdecia et al., 2000) or mouse (Muchmore et al., 2000) protein, survivin is a stable homodimer in solution, with the -COOH terminus a-helices protruding from the core dimer. A single-copy survivin gene located on chromosome 17q25 (human; Li et al., 1998) or 11E2 (mouse; Li and Altieri, 1999a) gives rise to three alternatively spliced survivin transcripts (Figure 1 ). In addition to wild-type survivin (142 amino acids), two survivin isoforms are generated by insertion of an alternative exon 2 (survivin-2B, 165 amino acids) or removal of exon 3 (survivin-DEx-3, 137 amino acids) (Mahotka et al., 1999) . In survivin-DEx-3, the splicing event introduces a frame shift that generates a unique -COOH terminus of potential functional significance (Mahotka et al., 2002) (Figure 1) .
A unique property of survivin is a sharp cell-cycledependent expression at mitosis. This is largely, but not exclusively, controlled at the level of gene transcription and involves canonical CDE/CHR boxes (Badie et al., 2000) in the survivin promoter (Kobayashi et al., 1999; Li and Altieri, 1999b) , acting as potential G1-repressor elements (Figure 2 ). Among the post-translational modifications that affect survivin levels, interest has recently focused on the control of protein stability. Survivin is a relatively short-lived protein ðt 1 2 ¼ 30 minÞ, and polyubiquitylation followed by proteasomal destruction has been shown to contribute to cell cycle periodicity by keeping survivin levels low at interphase (Zhao et al., 2000) . In addition, mitotic phosphorylation of survivin on Thr34 by p34cdc2-cyclin B1 has been associated with increased survivin stability at metaphase .
There are also examples of modulation of survivin expression independently of cell cycle progression. For CD34 þ bone-marrow-derived stem cells, stimulation with hematopoietic cytokines resulted in survivin expression in the absence of cyclin D and with hypophosphorylated Rb (Fukuda et al., 2002) , and vascular remodeling by angiopoietin-1 (Ang-1) upregulated survivin in nonproliferating endothelial cells (Papapetropoulos et al., 2000; Harfouche et al., 2002) . The search for signaling intermediates that control survivin expression has generated interesting findings (Figure 2 ). One common denominator of this pathway is the requirement for PI3-kinase/Akt activation, a general antiapoptotic signal (Datta et al., 1999) that has been implicated in the upregulation of survivin induced by GM-CSF, CSF and Ang-1 (Papapetropoulos et al., 2000; Carter et al., 2001; Fukuda et al., 2002) . In addition, for endothelial cells stimulated with nonmitogenic IL-11 (Mahboubi et al., 2001) , or pleural effusion lymphoma cells sustained by autocrine VEGF, IL-6 or IL-10 ( Aoki et al., 2003) , increased survivin expression was shown to be dependent on STAT3 activation. This is potentially important for the known role of STAT3 in cytoprotection , which may have direct consequences for oncogenic transformation (Turkson and Jove, 2000) (Figure 2 ).
Role of survivin in cell division
Upon expression at mitosis, survivin localizes to various components of the mitotic apparatus, including centrosomes, microtubules of the metaphase and anaphase spindle, and the remnants of the mitotic apparatusmidbodies (Li et al., 1998 Skoufias et al., 2000; Jiang et al., 2001; Fortugno et al., 2002) . A direct association between survivin and polymerized tubulin has been demonstrated in vitro (Li et al., 1998) , potentially involving the -COOH terminus a-helices (Figure 2) . A subcellular pool of survivin has also been localized to kinetochores of metaphase chromosomes Wheatley et al., 2001) , and may comprise up to B20% of total cellular survivin (Fortugno et al., 2002) . On the other hand, survivin is largely excluded from the nucleus (Fortugno et al., 2002) through a CRM1-dependent mechanism that may involve the survivin -COOH terminus (Rodriguez et al., 2002) .
The complex localization of survivin to the mitotic apparatus reflects its important function at cell division (Table 1 ). This first surfaced in targeting experiments using antisense or dominant-negative mutants, which resulted in a dual phenotype of apoptosis (see below) and aberrant mitotic progression, with supernumerary centrosomes, multipolar mitotic spindles, failed cytokinesis and multinucleation . Parallel experiments targeting survivin-like molecules in yeast (Uren et al., 1999) or C. elegans (Fraser et al., 1999 ) also revealed lethal cell division defects with failure to assemble a cleavage furrow and inability to complete cytokinesis. The phenotype of survivin knockout mice is consistent with an essential role of this pathway at mitosis . Beginning at embryonic day (E) 2.5, homozygous deletion of the survivin gene resulted in catastrophic defects of microtubule assembly, with absence of mitotic spindles, complete failure of cell division and multinucleation with 100% lethality by E 3.5-4.5 . An identical phenotype was independently confirmed on three different mouse genetic backgrounds (Conway et al., 2002) . Therefore, one model that has been put forward is that survivin functions in an essential and evolutionary conserved step in late-stage cell division, that is, cytokinesis, potentially involving cleavage furrow formation Adams et al., 2001) . In support of this, survivin was shown to form a complex with molecules thought to regulate cytokinesis, including Aurora B Figure 1 Structure-function of survivin proteins generated by alternative splicing. Organization of survivin and its alternatively spliced variants involving insertion of an alternative exon (survivin 2B) or skipping of exon 3 (survivin-DEx3). Discrete regions implicated in dimerization, microtubule binding, nuclear localization/export and subcellular targeting to mitochondria are indicated. Residues involved in the Zn 2 þ coordination sphere (Cys84) and increased protein stability following phosphorylation by p34cdc2 (Thr34) are shown Figure 2 Differential regulation of survivin expression in cell cycle-dependent and -independent pathways. Transcriptional and post-transcriptional mechanisms controlling survivin gene expression involve CDE/CHR G1 repressor elements in the survivin promoter. Non-cell-cycle-dependent mechanisms influencing survivin expression involve response to hematopoietic and vascular remodeling cytokines, STAT3-dependent signaling and PI3 kinase activity (Speliotes et al., 2000; Wheatley et al., 2001) , and to enhance the activity of Aurora B kinase in both mammalian cells (Chen et al., 2003) and Xenopus laevii (Bolton et al., 2002) . However, recent data demonstrate that this model is probably unsatisfactory. A broader role of survivin in cell division became apparent in antibody microinjection studies, which revealed a composite phenotype of prolonged metaphase arrest, occasionally followed by apoptosis, formation of multipolar mitotic spindles, and defects in chromosome attachments (Kallio et al., 2001; Giodini et al., 2002) . By immunofluorescence, cells microinjected with an antibody to survivin exhibited flattened and abortive mitotic spindles severely depleted of microtubules . Conversely, retroviral or adenoviral expression of survivin restored spindle stability and dynamics against microtubule poisons in tumor cells as well as endothelial cells (Tran et al., 2002) . Clearly, these data point to a much different model in which survivin participates in earlier phases of mitosis than cytokinesis, and is required for the assembly of a bipolar mitotic apparatus by controlling microtubule stability.
Is there a framework that reconciles these two sets of observations? One possibility is that the two pools of survivin localized to centrosomes/microtubules and kinetochores (Fortugno et al., 2002) actually mediate distinct functions at various phases of cell division: regulation of microtubule stability and spindle formation telephase congression and control of cleavage furrow formation of completion telophase. This is consistent with the observation that microtubule-and kinetochore-associated survivin are differentially regulated during the cell cycle, exhibit nonoverlapping patterns of phosphorylation, and are recognized by monoclonal antibodies in a mutually exclusive fashion (Fortugno et al., 2002) . Alternatively, the differently spliced survivin isoforms could mediate separate functions at cell division (Mahotka et al., 1999) . This remains a possibility that awaits formal testing when antibodies capable of discriminating between the various endogenous survivin isoforms become available. However, wild-type survivin is clearly the overwhelming form in all cell types tested so far (Mahotka et al., 1999) , and, at least in overexpression experiments, survivin-2B does not associate with the mitotic apparatus, and survivin-DEx-3 has actually been localized to the nucleus potentially through a bipartite nuclear localization signal in the new ÀCOOH terminus (Mahotka et al., 2002; Rodriguez et al., 2002) .
Perhaps a third and more inclusive possibility is that the various survivin pools provide a continuum in the dynamic regulation of the mitotic spindle checkpoint, from kinetochore dynamics through spindle assembly. This is consistent with recent data identifying a role for Aurora B in chromosome congression and microtubule arrangement at earlier stages of mitosis than cytokinesis (Shannon and Salmon, 2002) . In this context, a role of the Aurora/survivin complex in kinetochore dynamics (Bolton et al., 2002; Chen et al., 2003) may be integrated by microtubule survivin in the control of spindle formation upon entry into metaphase Tran et al., 2002) . A continuum regulation of the mitotic spindle checkpoint by survivin is also in line with antibody microinjection data, where inhibition of survivin abrogated cell cycle arrest in response to spindle poisons (Kallio et al., 2001) . This model is also satisfactory if one considers the biology of Aurora kinases, which, like survivin, are found frequently overexpressed in human cancers, and may participate in oncogenic transformation (Ota et al., 2002) (Table 1) . Altogether, the combined overexpression of both survivin and Aurora in cancer may obliterate the surveillance mechanism of the spindle assembly checkpoint, allowing cells with spindle defects, aberrant chromosome congression or misaligned/unattached kinetochores to proceed through cell division, thus enhancing tumor-associated aneuploidy.
Role of survivin in apoptosis inhibition
The question as to whether survivin had also a role in apoptosis inhibition, similar to other mammalian IAPs (Salvesen and Duckett, 2002) , or whether its function was limited to cell division, as with IAPs in yeast and C. elegans (Fraser et al., 1999; Uren et al., 1999) , has frequently been asked. This was dubbed as a 'controversy' that at times reached emotional tones (Adams et al., 2001; Silke and Vaux, 2001 ). However, the published record on this topic has been uniformly consistent, and not a single peer-reviewed article has appeared that experimentally refutes a role of survivin in apoptosis inhibition. Three lines of experimental evidence underscore this conclusion (Table 1) .
First, overexpression of survivin has been associated with inhibition of cell death initiated via the extrinsic or intrinsic apoptotic pathways (Ambrosini et al., 1997; Tamm et al., 1998; Kobayashi et al., 1999; Mahotka et al., 1999; Islam et al., 2000; Kasof and Gomes, 2000; Suzuki et al., 2000; Hoffman et al., 2001; Mirza et al., 2002; Zaffaroni et al., 2002) . Second, transgenic expression of survivin resulted in apoptosis inhibition in vivo (Grossman et al., 2001a) , and livers isolated from heterozygous survivin þ /À animals exhibited exaggerated apoptosis in response to suboptimal ligation of Fas (Conway et al., 2002) . Third, molecular antagonists of survivin including antisense, ribozymes, siRNA sequences or dominant-negative mutants resulted in caspase-dependent cell death, enhancement of apoptotic stimuli and anticancer activity, in vivo Chen et al., 2000; Kasof and Gomes, 2000; Olie et al., 2000; Jiang et al., 2001; Kanwar et al., 2001; Shankar et al., 2001; Xia et al., 2002; Yamamoto et al., 2002; Zhou et al., 2002; Choi et al., 2003; Pennati et al., 2003; Williams et al., 2003) . The apoptosis inhibitory function of survivin is evolutionary conserved, and a survivin-like molecule in Drosophila, Deterin, functions interchangeably with survivin to block apoptosis (Jones et al., 2000) in mammalian or insect cells (Jiang et al., 2001) .
Although the notion that survivin inhibits apoptosis is well established (Table 1) , elucidation of the mechanism(s) by which this occurs has not been straightforward. As with other IAPs (Salvesen and Duckett, 2002) , a physical interaction between survivin and initiator or effector caspases has been reported by several groups (Tamm et al., 1998; Kobayashi et al., 1999; Kasof and Gomes, 2000) , and a physical proximity between survivin and effector caspase-3 has been seen in vivo as well . However, with the exception of two published studies (Conway et al., 2000; Shin et al., 2001 ), this did not seem to translate in meaningful inhibition of caspase activity, in vitro (Banks et al., 2000; Kasof and Gomes, 2000; Verdecia et al., 2000) . In addition, the crystal structure of survivin does not suggest the presence of a 'hook and sinker' region that mediates caspase binding in other IAPs (Verdecia et al., 2000) , and the residues in the linker upstream BIR2 that in other IAPs (i.e. XIAP) dock to caspase-3 (Shi, 2002) are not present in survivin. One can take the view that this does not automatically rule out that survivin may still function as an inhibitor of effector caspases similar to other IAPs (Salvesen and Duckett, 2002) , and arguments to explain the lack of activity in cell-free systems may include folding requirements of the recombinant protein (Shin et al., 2001) , or the need for additional protein partners, in vivo. On the other hand, evidence is accumulating that survivin may play a more selective role than other IAPs in antagonizing mitochondrial-dependent apoptosis. Overexpression of survivin is more efficient at blocking mitochondrial-but not death-receptor-induced apoptosis (Grossman et al., 2001a) , a complex between survivin and the upstream mitochondrial initiator caspase-9 has been demonstrated in vivo (O'Connor et al., 2000a) , and survivin has been shown to associate with Smac/DIABLO (Du et al., 2000) , a mitochondrial-released apoptogenic protein that relieves the inhibitory effect of IAPs on caspase activation (Shi, 2002) . Moreover, cell death induced by molecular antagonists of survivin or by heterozygous reduction of survivin levels (Conway et al., 2002) has the characteristics of mitochondrial-dependent apoptosis with cytochrome c release (Mesri et al., 2001b) , caspase-9 activation (O'Connor et al., 2000a) , and involvement of the apoptosome components , caspase-9 and Apaf-1 (Wang, 2001) . Collectively, these data suggest that survivin, differently from other IAPs that inhibit initiator or effector caspases through their independent BIRs (Shi, 2002) , may selectively target the multimolecular process of caspase-9 activation. This pathway may well be centered on the survivin-Smac/DIABLO interaction (Du et al., 2000) , which was recently characterized in vitro and in vivo, and proposed as a critical modulator of caspase-9 processing during taxol-induced apoptosis (Song et al., 2003) . Additional data also implicate survivin, or at least its splice variant, survivin-DEx3, in mitochondrial-dependent apoptosis. It was recently reported that survivin-DEx3 contains a mitochondrial localization signal and a BH2 domain in the new -COOH terminus (Figure 1) , and that a survivin-DEx3-like molecule in the herpes simplex virus (HSV) genome localized to mitochondria and inhibited apoptosis by associating with Bcl-2 and by suppressing caspase-3 activity through its BIR . Whether survivin-DEx3 behaves similar to its viral counterpart remains to be seen, but its potential import to mitochondria would make it ideally suited to act, alone or by dimerizing with wild-type survivin, as an upstream regulator of mitochondrial-dependent apoptosis.
Role of survivin in cancer biology
A sharp differential expression in cancer versus normal tissues is one of the most intriguing features of survivin, and is unlike any other IAPs (Salvesen and Duckett, 2002) . Survivin is strongly and broadly expressed in embryonic and fetal organs (Adida et al., 1998b; Kobayashi et al., 1999) , but becomes undetectable in most terminally differentiated normal tissues (Ambrosini et al., 1997), perhaps with the exception of thymocytes (Ambrosini et al., 1997) , CD34 þ stem cells (Carter et al., 2001; Fukuda and Pelus, 2001 ) and basal colonic epithelial cells (Gianani et al., 2001; Zhang et al., 2001) . The strict developmental pattern of survivin expression is evolutionary conserved, and similar data were observed for survivin-like molecules in Drosophila (Jones et al., 2000) and X. laevii . By contrast, dramatic overexpression of survivin has been demonstrated in tumors of lung (Monzo et al., 1999) , breast (Tanaka et al., 2000) , colon (Kawasaki et al., 1998) , stomach , esophagus (Kato et al., 2001; Grabowski et al., 2003) , pancreas , liver , uterus (Saitoh et al., 1999) , ovaries (Yoshida et al., 2001 ), Hodgkin's disease (Garcia et al., 2003) , non-Hodgkin's lymphoma (Adida et al., 2000a; Kuttler et al., 2002) , leukemias Kamihira et al., 2001) , myelodysplastic syndrome with refractory anemia (Badran et al., 2003) , neuroblastoma (Adida et al., 1998a; Islam et al., 2000) , pheochromocytoma (Koch et al., 2002) , soft tissue sarcomas (Wurl et al., 2002 ), brain tumors (Chakravarti et al., 2002; Kajiwara et al., 2003) and melanoma Gradilone et al., 2003) . Genome-wide searches independently confirmed the differential expression of survivin in tumors versus normal tissues (Velculescu et al., 1999) . The two alternatively spliced forms of survivin are also differentially expressed in tumors (Hirohashi et al., 2002) .
Several retrospective studies used protein and/or nucleic acid detection strategies (immunohistochemistry, RT-PCR, in situ hybridization, DNA array profiling, etc.) to map the presence of survivin in various tumor series, and to determine its impact on disease parameters and clinical outcome. The results proved that survivin is a reliable marker of aggressive and unfavorable disease, signaling abbreviated overall survival (Kawasaki et al., 1998; Monzo et al., 1999; Adida et al., 2000a; Sarela et al., 2000; Tanaka et al., 2000; Kappler et al., 2001; Kato et al., 2001; Chakravarti et al., 2002; Wurl et al., 2002) , increased rates of recurrences (Swana et al., 1999) , resistance to therapy (Tran et al., 2002; Zaffaroni et al., 2002; Hausladen et al., 2003) and reduced apoptotic index, in vivo (Kawasaki et al., 1998; Tanaka et al., 2000; Satoh et al., 2001) . Array-based gene profiling studies are consistent with this view, identifying survivin as a 'riskassociated' gene for unfavorable outcome in breast cancer (van 't Veer et al., 2002) , large cell nonHodgkin's lymphoma (Kuttler et al., 2002) and colorectal cancer (van de Wetering et al., 2002; Williams et al., 2003) .
How does survivin bring about so many unfavorable consequences in tumors? Recent experiments of stepwise skin carcinogenesis in survivin transgenic mice began to address this question (Allen et al., 2003) . Skin tumor (papilloma) formation was actually found less frequently in survivin transgenic mice than in control littermates, whether or not on a wild-type or heterozygous p53 background (Allen et al., 2003) . However, papillomas never regressed in survivin transgenic mice and occasionally evolved into squamous carcinoma, whereas papillomas in control mice frequently regressed and never transitioned to squamous cell carcinoma (Allen et al., 2003) . These data suggest that survivin may participate in tumor progression rather than in the initial step of oncogenic transformation, and that its consequences may not become apparent until additional mutations are accumulated. This is consistent with the general paradigm that deregulated apoptosis inhibition contributes to malignancy by favoring the accumulation of additional 'cancer traits' (Hanahan and Weinberg, 2000) , codifying more aggressive disease behaviors (Evan and Vousden, 2001 ). The paradoxical 'protective' effect of survivin on the onset of skin tumors (Allen et al., 2003) mirrors similar data obtained with other apoptosis inhibitors, and may be explained as to the need for an initial wave of apoptosis of neighboring keratinocytes to allow physical expansion of the mutated cloned.
The molecular basis for the overexpression of survivin in cancer has been intensely investigated (Table 2) . Survivin gene transcription being linked to mitotic progression, it was originally thought that the overexpression seen in cancer simply reflected a higher number of proliferating cells, and that the proportion of cycling, potentially survivin-positive cells in normal tissues was below the limit of detection (Silke and Vaux, 2001 ). However, fresh experimental evidence discounted this view. First, comparable expression of survivin is found in tumors regardless of their mitotic indices , and, second, survivin reactivity is typically observed in the vast majority of tumor cells, in vivo, far exceeding the number of cycling cells detected by S-phase-specific markers. This has prompted an alternative possibility that the survivin gene may be globally deregulated in cancer, driving overexpression of the protein at all cell cycle phases, not just mitosis. Several experimental data are consistent with this view (Table 2) . Firstly, survivin promoter activity is largely silent in normal cell types but prominently expressed in tumor cell lines (Li and Altieri, 1999a) , and cells transfected with a reporter gene under the control of a survivin promoter exhibited cancer-specific activity, in vitro and in vivo (Bao et al., 2002) . Secondly, molecular lesions associated with cancer have been associated with deregulated survivin expression. These include amplification of the survivin locus on 17q25 in neuroblastoma (Islam et al., 2000) , demethylation of survivin exon 1 in ovarian cancer but not in normal ovaries (Hattori et al., 2001) , and, importantly, loss of p53. Three groups have independently reported that survivin is one of the genes that is transcriptionally repressed by wild-type p53 (Hoffman et al., 2001; Mirza et al., 2002; Zhou et al., 2002) . Although it is still unclear whether this involves a bipartite p53-responsive element in the survivin promoter (Hoffman et al., 2001) , or changes in chromatin structure (Mirza et al., 2002) , transcriptional repression of survivin contributed, at least in part, to p53-dependent apoptosis (Mirza et al., 2002; Zhou et al., 2002) , whereas survivin expression antagonized p53-induced cell death (Hoffman et al., 2001) . Another molecular abnormality of human cancer that was found to drive survivin expression is deregulated Wnt/TCF signaling (Zhang et al., 2001 ). This may be particularly relevant for the expression and role of survivin in colorectal cancer (Williams et al., 2003) , and is consistent with an embryonic-like pattern of survivin gene expression, potentially exploited during transformation (Zhang et al., 2001) (Table 2) .
Translational exploitation of survivin for cancer therapeutics therapy
The differential expression in cancer and what appears to be a requirement to preserve tumor cell viability identify survivin as a novel therapeutic target in cancer (Altieri, 2003) . Three independent strategies have generated promising results, and passed proof of principle in preclinical testing (Figure 3) . The first approach relied on the generation of an antigen-specific immune response against survivin-bearing tumor cells for potential cancer vaccination strategies (Andersen and Thor, 2002) . Survivin being selectively expressed in tumors, it may not be surprising that host T cells recognize it as a non-self-protein and mount a vigorous cytolytic and antibody response to survivin peptides, in vitro and in vivo (Rohayem et al., 2000; Schmitz et al., 2000; Andersen et al., 2001; Yagihashi et al., 2001; Hirohashi et al., 2002; Schmidt et al., 2003) . Indeed, HLA class I-restricted cytolytic T cells against survivin peptides have been demonstrated in patients with breast cancer, leukemia and melanoma, in vivo (Andersen et al., 2001) . The antibody response to survivin peptides may also offer concrete diagnostic opportunities, and detection of antibodies to survivin in combination with other cancer genes may provide a useful screening tool for patient follow-up strategies .
As anticipated above, a second approach involved the use of 'molecular antagonists', including antisense, ribozymes, siRNA and dominant-negative survivin mutants (Figure 3) . In these studies, interference with survivin expression/function resulted in suppression of tumor growth in various cancer models, alone or in combination with other anticancer strategies, and appearance of tumor cell apoptosis, in vivo (Kanwar et al., 2001; Grossman et al., 2001b; Yamamoto et al., 2002; Williams et al., 2003) .
A third strategy focused on pharmacologic inhibition of mitotic phosphorylation of survivin on Thr34 (Figure 3) . Mutation of Thr34 in survivin abolishes a phosphorylation site for the mitotic kinase p34cdc2 (O'Connor et al., 2000a) , and results in a dominantnegative phenotype with induction of apoptosis and anticancer activity, in vivo (Grossman et al., 2001b) . To reproduce this effect with a more flexible pharmacologic approach, antagonists of cyclin-dependent kinases (Cdk), flavopiridol (Sausville, 2002) , or the more p34cdc2-specific inhibitor, Purv.A (Gray et al., 1998) , were tested in tumor cells arrested at mitosis with taxol, which induces hyperphosphorylation of survivin on Thr34 (Zaffaroni et al., 2002) . With this protocol, sequential administration of the Cdk inhibitors resulted in escape from the mitotic block imposed by taxol, massive activation of mitochondrial-dependent apoptosis, and anticancer activity, in vivo Wall et al., 2003) . The reverse combination (Purv.A followed by taxol) was without effect, and Cdk inhibition after a mitotic block with depolymerized microtubules (mediated by vinca alkaloids) was also ineffective . This provided some mechanistic insights into the role of survivin in cytoprotection, and suggested that survivin functions in a relatively narrow time window at metaphase that requires elevated p34cdc2 activity and polymerized spindle microtubules. These data may also explain some conflicting results as to the actual role of p34cdc2 in apoptosis. A premature arrest of the cell cycle before the critical junction when the antiapoptotic function of survivin is required would be expected to have little effects on cell death, and, accordingly, early suppression of p34cdc2 activity by p21Waf1 has been associated with reduced apoptosis induced by taxol (Yu et al., 1998) .
It is difficult to predict which of these three modalities is likely to first see clinical testing in patients. New mechanistic insights have been obtained into the dominant-negative mode of action of the survivin Thr34Ala mutant (O'Connor et al., 2000a) . In protein turnover experiments, survivin Thr34Ala exhibited a 4-5-fold accelerated clearance , suggesting that dimerization of such unstable mutants with endogenous survivin may favor destruction of the heterocomplex and lower endogenous survivin levels below a critical antiapoptotic threshold. In addition, a replication-deficient adenovirus encoding survivin Thr34Ala has been recently generated, and shown to possess antitumor efficacy when locally administered by intratumor injection (Mesri et al., 2001b) , an approach that has already been validated in clinical trials for other anticancer gene therapy strategies, that is, p53 (Khuri et al., 2000) . On the other hand, progress has been made at improving the antitumor efficacy of antisense oligonucleotides, and various active sequences have been independently reported to suppress survivin expression and induce tumor cell apoptosis in vitro and in vivo Olie et al., 2000; Jiang et al., 2001; Kanwar et al., 2001; Xia et al., 2002) . Lastly, the antitumor activity of the sequential combination of taxanes followed by Cdk inhibition has already been validated in recent clinical trials in solid tumors (Schwartz et al., 2002) . Consistent with the in vitro data , these studies may pave the way for exploitation of a more selective class of Cdk inhibitors, which may exhibit improved specificity and reduced toxicity in sequential combination with taxanes.
There is, therefore, clear experimental evidence that interfering with survivin results in anticancer activity potentially suitable for clinical testing. But what are the actual cellular targets of survivin antagonists? The most intuitive hypothesis is that inhibition of survivin results in apoptosis of the proliferating tumor cell compartment, a model supported by the kinetics of apoptosis in cell cycle-synchronized cultures (O'Connor et al., 2000a) . However, there is evidence that survivin may Figure 3 Current approaches for survivin targeting in cancer therapy. Generation of antigen-specific cytolytic T cells against survivin peptides is being considered for cancer vaccination strategies. Molecular antagonists of survivin including antisense, siRNA, ribozymes and dominant-negative mutants induce spontaneous apoptosis, enhance cell death stimuli and inhibit tumor growth, in vivo. Inhibition of survivin phosphorylation on Thr34 by sequential administration of cyclin-dependent kinase inhibitors flavopiridol or Purv.A after mitotic arrest with stabilized microtubules (i.e. taxane) results in anticancer activity in vitro and in vivo. A similar response has been observed by adenoviral overexpression of a phosphorylation-deficient survivin Thr34Ala mutant (pAd-T34A) provide a broader cytoprotective role for the tumor microenvironment as a whole. This stemmed from the observation that survivin becomes strongly expressed in endothelial cells during the proliferative (Tran et al., 1999; O'Connor et al., 2000b) as well as remodeling (Papapetropoulos et al., 2000; Harfouche et al., 2002) phases of angiogenesis, and mediates apoptosis resistance in these cells (O'Connor et al., 2000b; Tran et al., 2002) . Conversely, antisense ablation of survivin during angiogenesis removed the cytoprotective effect of VEGF, caused endothelial cell apoptosis and prompted rapid involution of three-dimensional capillaries, in vitro (Mesri et al., 2001a) . Therefore, it is possible that molecular targeting of survivin may provide a dual advantage for anticancer strategies in vivo, by promoting tumor cell apoptosis and collapse of tumor-associated angiogenesis.
Concluding remarks
Over the past few years, compelling experimental evidence has accumulated to identify survivin as a unique member of the IAP gene family, positioned at the crossroad between cell death and mitotic progression. Through the contribution of several groups, the survivin pathway has emerged as a multifaceted and essential cellular infrastructure controlling chromosome congression, spindle microtubule function and also the upstream initiation of mitochondrial-dependent apoptosis. The original premise that this pathway was dramatically exploited in many human cancers (Ambrosini et al., 1997) was intensely scrutinized, and has now been unanimously validated. The blueprints as to how the survivin pathway may couple to mitotic transition and the control of apoptosis have recently come into better focus. However, how survivin is wired into the deep cellular circuitry controlling checkpoint function for cell proliferation and cell death in normal and transformed cells remains to be elucidated. An answer to these questions is expected to provide greater opportunities for the translational applicability of the survivin pathway in cancer diagnosis and therapy. 
